Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline.


Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
04 2022
Historique:
revised: 04 06 2021
received: 08 02 2021
accepted: 08 06 2021
pubmed: 27 7 2021
medline: 9 4 2022
entrez: 26 7 2021
Statut: ppublish

Résumé

The prognostic utility of cerebrospinal fluid (CSF) phosphorylated tau 217 (p-tau217) and p-tau181 is not understood. Analyses included 753 Mayo Clinic Study on Aging participants (median age = 71.6; 57% male). CSF amyloid beta (Aβ)42 and p-tau181 were measured with Elecsys immunoassays. CSF p-tau181 and p-tau217 were also measured with Meso Scale Discovery (MSD). We used Cox proportional hazards models for risk of mild cognitive impairment (MCI) and linear mixed models for risk of global and domain-specific cognitive decline and cortical thickness. Analyses were stratified by elevated brain amyloid based on CSF Aβ42 or amyloid positron emission tomography for those with imaging. CSF p-tau217 was superior to p-tau181 for the diagnosis of Alzheimer's disease (AD) pathology. CSF MSD p-tau181 and p-tau217 were associated with risk of MCI among amyloid-positive individuals. Differences between CSF p-tau measures predicting cortical thickness were subtle. There are subtle differences for CSF p-tau217 and p-tau181 as prognostic AD markers.

Identifiants

pubmed: 34310832
doi: 10.1002/alz.12415
pmc: PMC8789950
mid: NIHMS1720563
doi:

Substances chimiques

Amyloid beta-Peptides 0
Biomarkers 0
MAPT protein, human 0
tau Proteins 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

602-611

Subventions

Organisme : NIA NIH HHS
ID : R01 AG041851
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG034676
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG011378
Pays : United States
Organisme : NIA NIH HHS
ID : R33 AG058738
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062677
Pays : United States
Organisme : NIA NIH HHS
ID : R37 AG011378
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG006786
Pays : United States

Informations de copyright

© 2021 the Alzheimer's Association.

Références

Lancet Neurol. 2016 Jun;15(7):673-684
pubmed: 27068280
Clin Biochem. 2019 Oct;72:30-38
pubmed: 31129184
Sci Adv. 2020 Apr 15;6(16):eaaz2387
pubmed: 32426454
Brain. 2008 Mar;131(Pt 3):665-80
pubmed: 18263627
Ann Clin Transl Neurol. 2016 Jan 01;3(3):154-65
pubmed: 27042676
Neuroepidemiology. 2008;30(1):58-69
pubmed: 18259084
Nat Commun. 2020 Apr 3;11(1):1683
pubmed: 32246036
Arch Gen Psychiatry. 2004 Jan;61(1):95-102
pubmed: 14706948
J Nucl Med. 2009 Jun;50(6):878-86
pubmed: 19443597
Brain. 2020 Feb 1;143(2):650-660
pubmed: 31834365
Int J Epidemiol. 2012 Dec;41(6):1614-24
pubmed: 23159830
Alzheimers Res Ther. 2020 Mar 17;12(1):26
pubmed: 32183883
Alzheimers Dement. 2019 Nov;15(11):1437-1447
pubmed: 31668594
Acta Neuropathol Commun. 2018 Jun 29;6(1):52
pubmed: 29958544
Mol Chem Neuropathol. 1995 Dec;26(3):231-45
pubmed: 8748926
Nat Med. 2020 Mar;26(3):398-407
pubmed: 32161412
Front Aging Neurosci. 2019 May 21;11:121
pubmed: 31178717
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32725127
Alzheimers Dement. 2021 May;17(5):755-767
pubmed: 33252199
J Nucl Med. 2009 Mar;50(3):348-55
pubmed: 19223409
Front Mol Neurosci. 2014 May 13;7:42
pubmed: 24860424
J Intern Med. 2004 Sep;256(3):183-94
pubmed: 15324362
Alzheimers Dement. 2016 May;12(5):517-26
pubmed: 26555316
Lancet Neurol. 2017 Jun;16(6):435-444
pubmed: 28456479
Acta Neuropathol. 2019 Feb;137(2):279-296
pubmed: 30547227
EMBO Mol Med. 2020 Dec 7;12(12):e12921
pubmed: 33169916
Alzheimers Dement. 2017 Mar;13(3):205-216
pubmed: 27697430
J Cereb Blood Flow Metab. 2005 Nov;25(11):1528-47
pubmed: 15944649
Alzheimers Res Ther. 2019 Apr 22;11(1):34
pubmed: 31010420
Neurology. 2020 Dec 1;95(22):e3026-e3035
pubmed: 32973122

Auteurs

Michelle M Mielke (MM)

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Jeremiah A Aakre (JA)

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.

Alicia Algeciras-Schimnich (A)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Nicholas K Proctor (NK)

Eli Lilly and Company, Indianapolis, Indiana, USA.

Mary M Machulda (MM)

Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.

Udo Eichenlaub (U)

Roche Diagnostics GmbH, Penzberg, Germany.

David S Knopman (DS)

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Prashanthi Vemuri (P)

Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.

Jonathan Graff-Radford (J)

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Clifford R Jack (CR)

Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.

Ronald C Petersen (RC)

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Jeffrey L Dage (JL)

Eli Lilly and Company, Indianapolis, Indiana, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH